Maharashtra FDA flags up to 2,841% mark-up on hospital consumables
An IV infusion set available wholesale for Rs 11 carries an MRP of Rs 325, while a syringe costing under Rs 7 is priced around Rs 60. For pacemakers, heart valves and intraocular lenses, MRPs may be 10-30 times the import landed price. Maharashtra FDA commissioner Tukaram Mundhe posted on X that mark-ups run up to 2,841%, as most devices are not capped under the Drugs (Prices Control) Order, 2013, and urged the Centre to frame guidelines.
Source
Times of India — Top · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- An IV infusion set with a wholesale price of Rs 11 carries an MRP of Rs 325; a syringe available under Rs 7 is priced around Rs 60. — Specific figures appear in the source without naming the underlying data source.
- Mark-ups of up to 2,841% exist on commonly used hospital consumables. — Attributed to Maharashtra FDA commissioner Tukaram Mundhe in a post on X.
- MRPs of pacemakers, heart valves and intraocular lenses may be 10-30 times the import landed price. — Stated in source and echoed in AiMeD coordinator Rajiv Nath's quote.
- Most medical devices and consumables are not price-capped under the Drugs (Prices Control) Order, 2013. — Quoted directly from Mundhe's statement.
- NPPA capped cardiac stent and knee implant prices, and trade margins on pulse oximeters, BP monitors and glucometers were capped in 2020. — Presented as background fact in the source with no document cited.
Analysts’ view opinion
This is less a story about greed and more one about a hole in the regulatory architecture. The Drugs (Prices Control) Order, 2013 caps scheduled medicines, but most medical devices and consumables sit outside it — which is how an IV set bought at Rs 11 can legally carry an MRP of Rs 325. Notably, what the Maharashtra FDA commissioner is asking for is not a price cap but clear guidelines on the permissible gap between trade procurement price and declared MRP — in other words, trade margin rationalisation.
- The design gap lands directly on patients, since consumables are the least visible line in a hospital bill and inflate out-of-pocket treatment costs.
- The core unresolved question is one of authority: who actually sets a device's price — the manufacturer, the hospital or the regulator — an issue the story says has been flagged repeatedly over 15 years.
- India has policy precedent but only in fragments: NPPA capped cardiac stents and knee implants nearly a decade ago, and trade margins on items like pulse oximeters were capped during the 2020 pandemic — case-by-case interventions rather than a standing framework.
- Unusually, industry is not uniformly opposed this time: domestic body AiMeD has itself proposed capping margins at 75% for consumables and 50% for high-value devices, while MNC body MTAI has said it concurs with margin rationalisation, an inter-agency review and clearer guidelines.
- Implementation is the harder half: pricing here is a central subject, so a state FDA can spotlight but not fix it, and any framework will have to guard against the cost simply migrating to other billing heads such as procedure charges.
What to watch — Watch whether the Centre, through NPPA, moves to actual trade-margin guidelines or an inter-agency review for consumables and devices, or whether this remains another flag raised and left standing.
The story does not establish the Maharashtra FDA's methodology, how many products were examined, or which hospitals charged what — and no central response or policy decision has been finalised.
Deep dive
Research brief · 8 facts · 4 dates · exam-readyThe brief
Context
Medical devices and hospital consumables in India are largely outside statutory price control: only "scheduled" medicines are capped under the Drugs (Prices Control) Order, 2013. That leaves hospitals and suppliers free to print MRPs far above procurement or import landed cost, which inflates hospital bills and patients' out-of-pocket spending. Maharashtra FDA commissioner Tukaram Mundhe has revived a 15-year-old debate by flagging mark-ups of up to 2,841% on commonly used consumables and asking the Centre for guidelines on the permissible gap between trade procurement price and declared MRP. Industry bodies AiMeD (domestic) and MTaI (multinationals) have both weighed in on trade margin rationalisation.
Key facts
- An IV infusion set available in the wholesale market for Rs 11 carries an MRP of Rs 325.
- A disposable syringe available for under Rs 7 is priced at around Rs 60.
- For pacemakers, heart valves and intraocular lenses, the final MRP may be 10-30 times the import landed price.
- Maharashtra FDA commissioner Tukaram Mundhe flagged mark-ups as high as 2,841% on commonly used hospital consumables in a post on X on Tuesday.
- Scheduled medicines are capped under the Drugs (Prices Control) Order, 2013; most medical devices and consumables are not.
- NPPA analyses of hospital bills showed some private hospitals procured consumables at rock-bottom prices but charged patients the high printed MRP.
- Cardiac stents and orthopaedic knee implants were price-capped by NPPA nearly a decade ago.
- AiMeD has proposed capping trade margins at 75% for consumables such as syringes and IV sets, and at 50% for high-value devices such as pacemakers and heart valves.
Timeline
- Over the last 15 yearsThe issue of steep medical device mark-ups flagged multiple times but left unresolved.
- Nearly a decade agoNPPA capped prices of cardiac stents and orthopaedic knee implants.
- 2020 (Covid-19 pandemic)Government capped trade margins on certain critical items including pulse oximeters, blood pressure monitors and glucometers.
- Tuesday (as reported)Maharashtra FDA commissioner Tukaram Mundhe posted on X flagging mark-ups up to 2,841% and urged the Centre to frame guidelines.
Who has a stake
- Patients — Inflated MRPs on consumables and implants raise hospital bills and out-of-pocket treatment costs.
- Maharashtra Food and Drug Administration (Tukaram Mundhe) — Has flagged the structural regulatory gap and is pressing the Centre for guidelines on procurement price-MRP gaps.
- National Pharmaceutical Pricing Authority (NPPA) — Central price regulator that capped stents and knee implants and has analysed hospital billing patterns.
- Private hospitals — Accused of buying consumables cheap and billing patients at high printed MRP; face possible margin caps.
- AiMeD (domestic device industry, Rajiv Nath) — Says ethical manufacturers lose out to unchecked hospital mark-ups; proposes 75% and 50% trade margin caps.
- Medical Technology Association of India (MTaI, MNCs) — Concurs with margin rationalisation, inter-agency review and clear guidelines on procurement cost-MRP gap.
Why it matters
Consumables and implants are among the least visible items on a hospital bill, yet mark-ups running into hundreds or thousands of per cent can decide whether a family is pushed into distress spending. Because most devices sit outside the Drugs (Prices Control) Order, 2013, neither the price nor the information around it is monitored, so patients cannot compare or contest what they are charged. The rare convergence of domestic and multinational industry bodies on trade margin rationalisation makes central action politically feasible.
UPSC angle
Prelims pointers
- Drugs (Prices Control) Order, 2013 caps prices of scheduled medicines; most medical devices and consumables are outside it.
- NPPA is the body that capped cardiac stent and orthopaedic knee implant prices nearly a decade ago.
- In 2020, trade margins were capped on pulse oximeters, blood pressure monitors and glucometers during the pandemic.
- AiMeD represents domestic device makers; MTaI represents multinational medical technology firms.
- Tukaram Mundhe is Maharashtra FDA commissioner; he flagged mark-ups up to 2,841% on hospital consumables.
- Trade margin rationalisation means limiting the permissible gap between trade procurement price and declared MRP.
Mains framing
The core issue is a structural regulatory gap: India's price control architecture, built around the Drugs (Prices Control) Order, 2013, covers scheduled medicines but leaves most medical devices and consumables uncapped, so the declared MRP bears little relation to the wholesale or import landed price — an IV set bought at Rs 11 is printed at Rs 325, a syringe under Rs 7 sells at Rs 60, and pacemakers, heart valves and intraocular lenses carry MRPs 10-30 times landed cost. The consequence is twofold: patients absorb mark-ups reported to reach 2,841% as out-of-pocket expenditure, and the market perversely rewards suppliers willing to inflate MRPs, squeezing out those who price transparently on ex-factory or landed cost, as AiMeD argues. Past interventions have been episodic and product-specific — NPPA's stent and knee implant caps, and the 2020 caps on pulse oximeters, BP monitors and glucometers — rather than systemic. The way forward suggested by the actors themselves is trade margin rationalisation: central guidelines fixing the permissible gap between trade procurement price and declared MRP, an inter-agency review, and greater price transparency, with AiMeD proposing 75% caps on common consumables and 50% on high-value devices. The unresolved question the story poses — whether the manufacturer, the hospital or the regulator sets device prices — is the one any reform must answer.
Key terms
- MRP (Maximum Retail Price)
- The printed price at which a product is billed to the patient, often far above procurement or landed cost for devices.
- Drugs (Prices Control) Order, 2013
- The order under which prices of scheduled medicines are capped; most medical devices and consumables fall outside it.
- NPPA
- National Pharmaceutical Pricing Authority, the central price regulator that capped cardiac stents and knee implants.
- Trade margin rationalisation
- Limiting the permissible gap between the trade procurement price and the declared MRP of a product.
- Import landed price
- The cost of an imported device after freight, duties and charges, used as the base for judging mark-ups.
- AiMeD / MTaI
- Association of Indian Medical Device Industry (domestic makers) and Medical Technology Association of India (multinationals).
Practice questions
- Most medical devices remain outside statutory price control in India. Examine how this affects out-of-pocket health expenditure and suggest a regulatory framework.
- Compare product-specific price capping (as done for cardiac stents and knee implants) with across-the-board trade margin rationalisation as tools of health price regulation.
- "Who sets the price of a medical device - the manufacturer, the hospital or the regulator?" Discuss with reference to the Drugs (Prices Control) Order, 2013 and the role of the NPPA.
Grounded only in the source report — figures and dates are the source's, not inferred.